Understanding how metabolism drives acute myeloid leukemia
Official title: Interrogation of the oxidative-stress-induced leukemia program in vivo using metabolic imaging
Funded at Sloan-Kettering Inst Can Research · NIH-11123417 · Data updated 2026-11-12
This research explores how specific metabolic changes in leukemia cells could lead to new ways to treat acute myeloid leukemia (AML), especially for patients whose disease returns or resists current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $711,338 |
| NIH project number | 5R01CA283578-03 |
| Project ID | NIH-11123417 on NIH RePORTER |
Who could benefit from this research
✓Could help
This research is most relevant to patients with acute myeloid leukemia, especially those whose disease has returned or is no longer responding to current therapies.
✕Less likely to help
Patients without acute myeloid leukemia or those whose disease does not involve the specific metabolic pathways being studied may not directly benefit from this particular research.
What this research studies
Acute myeloid leukemia (AML) is a complex cancer where many patients experience their disease returning or becoming resistant to initial treatments. This project aims to uncover unique metabolic features within AML cells that could be targeted with new medicines. We are particularly interested in how leukemia cells use sugar and other nutrients differently, focusing on an enzyme called PHGDH. By understanding and potentially blocking this enzyme, we hope to find new vulnerabilities in these cancer cells. This work builds on previous discoveries about leukemia's metabolism, seeking to develop more effective strategies for patients.
Why it matters
Potential benefit: If successful, this work could lead to the development of new drug targets and therapies for acute myeloid leukemia, particularly for patients who have relapsed or become resistant to existing treatments.
How similar studies have gone: Previous work by this research team has successfully identified new metabolic vulnerabilities in leukemia, providing a strong foundation for this current approach.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Keshari, Kayvan R — Sloan-Kettering Inst Can Research
- Study coordinator: Keshari, Kayvan R
Related research
Other NIH-funded projects on the same topics.
-
Targeting leukemia metabolism with metabolic imaging in AML
Researchers are testing a new way to image and target the energy metabolism of acute myeloid leukemia to find vulnerabilities that could lead to better treatments.
-
Exploring how oxidative stress affects leukemia using advanced imaging techniques
This study is looking at how stress affects the metabolism of acute myeloid leukemia (AML) cells, hoping to find weaknesses that could lead to new treatments, so patients can learn more about their specific type of leukemia and possible new options for care.
-
Investigating how oxidative stress affects leukemia using advanced imaging techniques
This study is looking at how stress in the body affects the way leukemia cells use sugar to grow, with the goal of finding new ways to treat acute myeloid leukemia (AML) and help patients feel better.
-
Investigating a specific type of leukemia in children caused by genetic changes.
This study is looking at how certain proteins linked to leukemia affect kids and teens with high-risk blood cancers, and the researchers hope to find new ways to treat these conditions by learning more about how the disease works.
-
Caregiver-led mobile tool to support healthy habits for kids treated for ALL
A caregiver-directed mobile program helps children who were treated for acute lymphoblastic leukemia build healthier daily routines.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.